Senate Finance Panel’s New Legislative Staffer Kaltenboeck Likes QALYs For Valuing Drugs
Anna Kaltenboeck joins the committee from Memorial Sloan Kettering’s health policy group, which has been an active participant in US drug pricing reform policy development and a critic of the biopharma industry, often through public commentary by its director, Peter Bach.
You may also be interested in...
Ron Wyden points to expectations Biogen’s drug will impose a heavy cost burden on Medicare as he questions FDA’s decision to approve aducanumab. He also expresses interest in a government-sponsored technology assessment program that could help establish the value of drugs.
Biopharma draws a line in the sand on drug pricing reform and offers to come to the table, but given the fracturing support for Rx legislation within the Democratic caucus, industry may not have as much need to negotiate with Congress. More detail on industry’s latest proposals for lowering costs may come in the second half.
Groups oppose use of quality-adjusted life year metric, noting ICER’s work is becoming more influential among payers. However, patient advocates do not suggest a uniform methodological alternative.